Skip to main content
Signal8
Launch Terminal

Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Specialties

Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc.

NASDAQ:ANIKHealthcare
-3.85%$20.95
AH$20.95+0.00%vs close
Mkt Cap$280.37M
Float11.57M
O/S13.38M
Vol
$ Vol
RVOL
Inst Own91.2%
SI3.2%
Earnings
Dilution
Anika Therapeutics, Inc. logoNASDAQ:ANIK$20.95-3.85%
Phase Distribution
17 lead-sponsored trials·2 active·14 completed
Phase 34
Not applicable13
(2 more as collaborator)
Status Overview
Recruiting1
Active, not recruiting1
Completed14
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Repeat Injection of Cingal® for Osteoarthritis of the Knee

    Cingal, Cingal

    Osteoarthritis of the Knee

    Enrollment
    242
    Start
    Feb 2015
    Primary Completion
    Apr 2015
    Completion
    May 2015
    NCT02381652
  • Phase 3
    Completed

    Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide

    Triamcinolone Hexacetonide

    Knee Osteoarthritis

    Enrollment
    576
    Start
    May 2017
    Primary Completion
    Apr 2018
    Completion
    Apr 2018
    NCT03191903
  • Phase 3
    Completed

    Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up

    Triamcinolone Hexacetonide

    Knee Osteoarthritis

    Enrollment
    526
    Start
    Dec 2017
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT03390036
  • Phase 3
    Completed

    Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain

    Cingal, Triamcinolone Hexacetonide (TH)

    Osteoarthritis, Knee

    Enrollment
    231
    Start
    Sep 2020
    Primary Completion
    May 2022
    Completion
    May 2022
    NCT04231318
  • Not applicable
    Completed

    Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee

    Monovisc®, Saline

    Osteoarthritis

    Enrollment
    369
    Start
    Jan 2008
    Primary Completion
    Dec 2009
    Completion
    Feb 2010
    NCT00653432
  • Not applicable
    Completed

    Safety Study of Cosmetic Tissue Augmentation in People of Color

    Elevess

    Wrinkles

    Enrollment
    100
    Start
    Mar 2009
    Primary Completion
    Dec 2009
    Completion
    Aug 2010
    NCT01147172
  • Not applicable
    Completed

    Cingal Study for Knee Osteoarthritis

    Hyaluronic Acid and TH (Cingal®), Hyaluronic Acid (Monovisc®)

    Knee Osteoarthritis

    Enrollment
    368
    Start
    Jun 2013
    Primary Completion
    May 2014
    Completion
    Sep 2014
    NCT01891396
  • Not applicable
    Active, not recruiting

    HyaloFAST Trial for Repair of Articular Cartilage in the Knee

    Hyalofast, Microfracture

    Defect of Articular Cartilage

    Enrollment
    200
    Start
    Dec 2015
    Primary Completion
    Mar 2025
    Completion
    Jun 2026est.
    NCT02659215
  • Not applicable
    Withdrawn

    Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow)

    OVT (Sodium Hyaluronate), Saline

    Epicondylitis, Tennis Elbow +1

    Enrollment
    0
    Start
    Sep 2025est.
    Primary Completion
    Apr 2027est.
    Completion
    Oct 2027est.
    NCT02861183
  • Not applicable
    Completed

    OVT for Epicondylosis (Tennis Elbow)

    OrthoVisc®-T (OVT)

    Epicondylitis, Lateral, Tendinopathy, Elbow

    Enrollment
    50
    Start
    Jul 2019
    Primary Completion
    Dec 2020
    Completion
    Dec 2020
    NCT04026191
  • Not applicable
    Completed

    MONOVISC for Hip Joint Pain Relief Due to Osteoarthritis

    Monovisc

    Osteoarthritis, Hip

    Enrollment
    25
    Start
    Dec 2019
    Primary Completion
    Feb 2021
    Completion
    Mar 2021
    NCT04204083
  • Not applicable
    Completed

    MONOVISC for Shoulder Joint Pain Relief Due to Osteoarthritis

    Monovisc

    Osteo Arthritis Shoulders

    Enrollment
    25
    Start
    Dec 2019
    Primary Completion
    Feb 2021
    Completion
    Mar 2021
    NCT04204265
  • Not applicable
    Completed

    MONOVISC for Ankle Joint Pain Relief Due to Osteoarthritis

    Monovisc

    Osteoarthritis Ankle

    Enrollment
    25
    Start
    Dec 2019
    Primary Completion
    Feb 2021
    Completion
    Mar 2021
    NCT04204278
  • Not applicable
    Completed

    Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip Joint

    Cingal

    Osteoarthritis, Hip

    Enrollment
    25
    Start
    Jan 2021
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT04640298
  • Not applicable
    Completed

    Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder Joint

    Cingal

    Osteoarthritis, Shoulder

    Enrollment
    25
    Start
    Jan 2021
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT04640961
  • Not applicable
    Completed

    Study of Cingal® for Symptomatic Relief of Osteoarthritis of Ankle Joint

    Cingal

    Osteoarthritis, Ankle

    Enrollment
    25
    Start
    Jan 2021
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT04640974
  • Not applicable
    Recruiting

    Integrity Implant System Post Market Clinical Follow-Up Study

    Integrity Implant System

    Rotator Cuff Tears of the Shoulder

    Enrollment
    150
    Start
    Feb 2025
    Primary Completion
    Jun 2027est.
    Completion
    Oct 2027est.
    NCT06741527
Search ClinicalTrials.gov for “Anika Therapeutics”